|
|
Article: Claritin may enter the O-T-C market. (Supplier News).(Schering-Plough Corp.)(Brief Article)
- Article from:
- Chain Drug Review
- Article date:
- April 1, 2002
CopyrightCOPYRIGHT 2002 Racher Press, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KENILWORTH, N.J. -- Schering-Plough Corp. hopes to blunt the impact of possible generics competition for Claritin (loratadine) by asking the Food and Drug Administration to switch all indications and formulations of its popular allergy product to over-the-counter status.
Claritin generated more than $3 billion in sales in 2001, nearly one-third of the company's revenues.
The action by the drug maker is a reversal of the position it took last year when Wellpoint Pharmacy Management petitioned the FDA for such a change. Since then Schering-Plough has brought out Clarinex, which it calls the first non-sedating antihistamine for treating both year-round ...